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Evaluation of a chemoresponse assay as
a predictive marker in the treatment of
recurrent ovarian cancer: further analysis of
a prospective study
C Tian1, D J Sargent2, T C Krivak3, M A Powell4, M J Gabrin1, S L Brower*,1 and R L Coleman5
1

Precision Therapeutics, Inc., 2516 Jane Street, Pittsburgh, PA 15203, USA; 2Health Sciences Research, Mayo Clinic, 200 First Street
SW, Rochester, MN 55905, USA; 3The Western Pennsylvania Hospital, 4800 Friendship Avenue, Pittsburgh, PA 15224, USA;
4
Washington University School of Medicine, 4911 Barnes-Jewish Hospital Plaza, St. Louis, MO 63110, USA and 5University of Texas
MD Anderson Cancer Center, 1155 Herman Pressler Drive, Houston, TX 77030, USA
Background: Recently, a prospective study reported improved clinical outcomes for recurrent ovarian cancer patients treated with
chemotherapies indicated to be sensitive by a chemoresponse assay, compared with those patients treated with non-sensitive
therapies, thereby demonstrating the assay’s prognostic properties. Due to cross-drug response over different treatments and
possible association of in vitro chemosensitivity of a tumour with its inherent biology, further analysis is required to ascertain
whether the assay performs as a predictive marker as well.
Methods: Women with persistent or recurrent epithelial ovarian cancer (n ¼ 262) were empirically treated with one of 15 therapies,
blinded to assay results. Each patient’s tumour was assayed for responsiveness to the 15 therapies. The assay’s ability to predict
progression-free survival (PFS) was assessed by comparing the association when the assayed therapy matches the administered
therapy (match) with the association when the assayed therapy is randomly selected, not necessarily matching the administered
therapy (mismatch).
Results: Patients treated with assay-sensitive therapies had improved PFS vs patients treated with non-sensitive therapies, with the
assay result for match significantly associated with PFS (hazard ratio (HR) ¼ 0.67, 95% confidence interval (CI) ¼ 0.50–0.91,
P ¼ 0.009). On the basis of 3000 simulations, the mean HR for mismatch was 0.81 (95% range ¼ 0.66–0.99), with 3.4% of HRs less
than 0.67, indicating that HR for match is lower than for mismatch. While 47% of tumours were non-sensitive to all assayed
therapies and 9% were sensitive to all, 44% displayed heterogeneity in assay results. Improved outcome was associated with the
administration of an assay-sensitive therapy, regardless of homogeneous or heterogeneous assay responses across all of the
assayed therapies.
Conclusions: These analyses provide supportive evidence that this chemoresponse assay is a predictive marker, demonstrating its
ability to discern specific therapies that are likely to be more effective among multiple alternatives.

Clinical management in the recurrent epithelial ovarian
cancer (EOC) setting is not standardized. Although numerous
chemotherapeutic regimens are currently recommended (National
Comprehensive Cancer Network, 2013a), there is insufficient

evidence from clinical trials to demonstrate that any single
treatment is superior to any other, particularly in terms of overall
survival (OS; Coleman et al, 2013), and, in practice, the choice
of treatment remains empiric. Chemoresponse assays are one
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approach that has the potential to improve the selection of a
clinically effective therapy among the many options. Although
there have been multiple studies providing encouraging data, the
use of chemoresponse assays in the treatment of recurrent EOC
continues to be debated (Schrag et al, 2004; Burstein et al, 2011).
Most of the previous chemoresponse assay studies in EOC were
retrospective analyses evaluating patients who had tissues assayed
over many years, making it difficult to ensure the quality of the
assay data and its consistency with the clinical data (Holloway et al,
2002; Matsuo et al, 2010; Pant et al, 2010). Recently, a large,
prospective study evaluating the clinical relevance of a chemoresponse assay (ChemoFx, Precision Therapeutics, Inc., Pittsburgh,
PA, USA) in recurrent or persistent EOC was reported (Rutherford
et al, 2013). The study showed a significant improvement in the
clinical outcome for patients treated with therapies to which their
tumours were assayed as sensitive compared with those treated
with therapies assayed as non-sensitive, supporting the clinical
benefit of the assay. However, questions remain regarding this
assay’s prognostic and/or predictive utility given that (1) crossdrug response is common in ovarian cancer (i.e., if a tumour is
sensitive to treatment A, then the same tumour may also be
sensitive to treatments B, C, D, etc.), making it challenging to select
a specific therapy among the multiple available treatments; and (2)
the assay may simply reflect the intrinsic biology of a tumour (i.e.,
patients with assay-sensitive treatment results may simply have
better prognoses than patients with assay-resistant results, regardless of the treatment clinically administered) and, thus, this assay
may have only a prognostic role. As such, it is important to further
evaluate the ability of this assay to function as a predictive marker,
that is, select specific effective therapies for personalised treatment.
A prognostic marker is a clinical or biological characteristic that
‘identifies patients with differing risks of a specific outcome, such
as progression or death’ (Sargent et al, 2005), regardless of
treatment administered. Prognostic markers are helpful for
identifying patients that are at high risk of relapse and therefore
are potential candidates for alternative management strategies. In
contrast, predictive markers ‘are associated with response (benefit)
or lack of response to a particular therapy relative to other available
therapy’ (McShane, 2012) and can be used to identify patients most
likely to benefit from a specific therapy. In a clinical setting where a
number of treatment options with similar impact on patient
outcome are available, the utility of a predictive marker for
individualised therapy would generally be greater than the utility of
a prognostic marker.
The current study sought to address whether this chemoresponse assay could function as a predictive marker, with the
capacity to discern specific therapies that are likely to be more
effective and those that are not. The study results reported herein
are consistent with REMARK guidelines (McShane et al, 2005).

MATERIALS AND METHODS

Study Population. The current analyses were conducted using the
evaluable cohort of 262 women with persistent or recurrent EOC
from a recent prospective, multisite, noninterventional clinical
study (Trial registration ID: NCT00288275; Rutherford et al,
2013). All patients were enrolled under an IRB approved protocol
and provided written informed consent consistent with all federal,
state and local regulations before participating in the study. The
study design, patient eligibility, chemoresponse assay methodology
and patient outcome assessment have been described elsewhere
(Rutherford et al, 2013). Briefly, patients were treated with one of
15 prospectively defined, common chemotherapy options available
for recurrent EOC (National Comprehensive Cancer Network,
2013a), based on the medical judgment of the oncologist who was
844
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blinded to the assay results. Fresh tissue tumour samples were
collected at the time of recurrence and then assayed for
chemoresponse against this panel of therapies. Each therapy for
each patient tumour sample was classified by the assay as sensitive
(S), intermediate (I) or resistant (R). A CONSORT diagram
describing the study population is presented as Supplementary
Figure 1.
Statistical analysis. The primary endpoint of this study was
progression-free survival (PFS), defined as the length of time from
the start of therapy until the date of first-documented disease
progression or death. Disease progression was measured by
radiologic examination, physical examination and CA-125 measurements using RECIST or GCIC criteria. Assessment was
performed every other cycle during the treatment, every 3 months
for the first 2 years, every 6 months for the next 3 years and
annually thereafter. The association of chemoresponse assay results
with PFS was assessed using the Cox proportional hazards model
(Cox, 1972); the proportional hazards assumption was tested by
examining the relationship between scaled Schoenfeld residuals
and time (Grambsch and Therneau, 1994). The Kaplan–Meier
method was used to estimate the probability and duration of PFS
(Kaplan and Meier, 1958), and the log-rank test was used to test for
the differences between PFS curves by assay category (Peto and
Peto, 1972).
Several novel approaches were used to evaluate the predictive
value of the assay (Supplementary Figure 2). First, association of
the assay with PFS was compared between match and mismatch
analyses. The match analysis was performed using the assay result
for the administered therapy (assayed therapy ¼ administered
chemotherapy) for each patient; the mismatch analysis was
performed using the assay results for a treatment randomly
selected from all assayed treatments, not necessarily matching the
administered therapy, for each patient (assayed therapyaadministered chemotherapy). Both univariate and multivariate analyses
controlling for other clinical factors were conducted. Using this
approach, if the assay is neither prognostic nor predictive, the HR
of PFS for assay-sensitive vs assay-non-sensitive for both match
and mismatch would be 1.0; if the assay is only prognostic, then
both HRs for match and mismatch would be o1.0 and have
identical values. However, if the assay has both prognostic and
predictive value, then both HRs for PFS for match and mismatch
would be o1.0, and the HR for match would be lower than HR for
mismatch. In short, if the assay is a predictive marker, then the
association of PFS with match assays is expected to be stronger
than with mismatch assays. To obtain the HR for mismatch, the
assay result for one therapy for each patient was randomly selected
with equal probability from the (up to) 15 study-designated
therapies, and the association with PFS was calculated. This
procedure was repeated 3000 times and the mean HR for mismatch
was assessed.
Second, the influence of cross-drug response (either sensitivity
or resistance to all assayed therapies) was evaluated by calculating a
multiple drug response index (MDRI). This index represents the
percentage of all assayed therapies to which a patient scored as
number of sensitive therapies
sensitive ðMDRI ¼ total
number of therapies assayed 100 % Þ. Patients
were classified into four groups based on their MDRI and
administered clinical treatment: sensitive to all assayed therapies
(MDRI ¼ 100%) and therefore treated with a sensitive therapy
(SA), sensitive to some therapies (0oMDRIo100%) and treated
with a sensitive therapy (SP), non-sensitive to all therapies
(MDRI ¼ 0) and therefore treated with a non-sensitive therapy
(RA), and non-sensitive to some therapies (0oMDRIo100%) and
treated with a non-sensitive therapy (RP). This analysis investigates
if the observed association between assay result and clinical
outcome is driven by the inherent chemosensitivity of the tumour
(i.e., homogeneous response to all therapies) or is due to the ability
www.bjcancer.com | DOI:10.1038/bjc.2014.375
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of the assay to specifically identify sensitive therapies. In this
approach, the chemoresponse assay is suggested to be a predictive
marker when the PFS for sensitive categories (SA, SP) differs from
the PFS for non-sensitive categories (RA, RP) and no substantial
difference is observed within each category (SA vs SP and RA vs
RP). In other words, PFS should be associated with the
chemosensitivity of the tumour for the administered therapy,
independent of MDRI (i.e., regardless of homogeneous or
heterogeneous assay responses across all of the assayed therapies).
In addition, a two-dimensional clustering analysis was
conducted using the chemoresponse assay scores for seven
single-agent therapies (carboplatin, cisplatin, gemcitabine, pegylated liposomal doxorubicin (PLD), paclitaxel, docetaxel and
topotecan). These seven agents, alone or in combination, comprise
the 15 treatments included in this study. This analysis examines the
level of correlation between assay results for different therapies and
also explores whether patients could be clustered into distinct
groups, based on their assay results. If the assay simply reflects the
intrinsic biology of a tumour, these clusters may have different
prognostic profiles. The clustering analysis was performed using a
hierarchical clustering algorithm based on the complete linkage
method (Kaufman and Rousseeuw, 1990).
All analyses were performed using SAS version 9.3 (SAS Institute,
Cary, NC, USA), except for clustering analysis which was implemented using R version 3.01 (cran.r-project.org). All reported P-values
are two-sided with Po0.05 considered statistically significant.
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Table 1. Patient characteristics

Number of patients (%)
N ¼ 262
Age (years)
Median (range)

61 (24–93)

Race
Caucasian
African American
Others

234 (89.3)
14 (5.3)
14 (5.3)

ECOG performance status
0
1
2

183 (69.6)
66 (25.2)
13 (5.0)

Histology
Serous
Endometrioid
Clear cell
Mucinous
Adenocarcinoma, NOS
Others

178
19
19
3
30
13

(67.9)
(7.3)
(7.3)
(1.3)
(11.5)
(5.0)

12
33
168
49

(4.6)
(12.6)
(64.1)
(18.7)

Tumour grade

RESULTS

A total of 335 patients were clinically eligible for inclusion in the
study, with 262 of them evaluable for analysis. Patient characteristics for the 262 patient cohort have been previously reported
(Rutherford et al, 2013) (Table 1) and are comparable to the
superset of clinically eligible patients (Supplementary Table 1). Of
the 15 therapies prospectively defined in the protocol, 12 were
administered clinically, including both single agent and combination therapies (Rutherford et al, 2013).
Association of clinical outcome with chemoresponse assay
results: match/mismatch analysis. As previously reported, the
assay result for match was significantly associated with PFS
(HR ¼ 0.67, 95% CI ¼ 0.50–0.91, P ¼ 0.009), with patients treated
with an assay-sensitive therapy showing an improvement in PFS as
compared with assay-non-sensitive (I þ R) patients (Figure 1). This
association was consistent after controlling for clinical covariates
(HR ¼ 0.66, 95% CI ¼ 0.47–0.94, P ¼ 0.020; Rutherford et al, 2013).
The average prognostic value of assay results for multiple different
therapies was examined using the assay results for mismatch, in
which the assay result for one treatment was randomly selected
from the (up to) 15 designated therapies with equal probability for
each patient, and the association with PFS was estimated. Based on
3000 repeated re-samplings, the mean HR for mismatch was 0.81
(95% range ¼ 0.66–0.99) (Figure 2A). Based on the distribution of
HRs for mismatch, only 3.4% of HRs were o0.67 (Figure 2A).
When multivariate analysis was performed, the HRs were 0.66 and
0.88, based on match and mismatch, respectively, with only 0.7% of
HRs from mismatch o0.66 (Figure 2B). The results for OS were
similar. In univariate analysis, the HRs for death were 0.61 and
0.76, based on match and mismatch, respectively, with 5.3% of HRs
from mismatch o0.61; in multivariate analysis, the HRs were 0.59
and 0.79, based on match and mismatch, respectively, with 3.6% of
HRs from mismatch o0.59. The HRs obtained from both match
and mismatch analyses demonstrate the prognostic value of the
assay (i.e., HR for both match and mismatch are significantly less
than 1.0). More importantly, these results also indicate that the HR
www.bjcancer.com | DOI:10.1038/bjc.2014.375

1
2
3
Unknown

Platinum sensitivity status
Platinum-sensitive
Platinum-resistant

145 (55.3)
117 (44.7)

Type of chemotherapy
Carboplatin/Paclitaxel
Liposomal Doxorubicin
Carboplatin/Gemcitabine
Topotecan
Carboplatin
Carboplatin/Docetaxel
Cisplatin/Gemcitabine
Cisplatin/Paclitaxel
Gemcitabine
Paclitaxel
Carboplatin/Topotecan
Cisplatin

79
55
25
22
15
15
15
13
9
5
5
4

(30.2)
(21.0)
(9.5)
(8.4)
(5.7)
(5.7)
(5.3)
(5.0)
(3.4)
(1.9)
(1.9)
(1.5)

Clinical prognoses
Alive without progression
Alive with progression
Dead

33 (12.6)
67 (25.6)
162 (61.8)

Abbreviations: ECOG ¼ Eastern Cooperative Oncology Group; NOS ¼ not otherwise
specified. Reproduced by kind permission of Elsevier from Rutherford et al (2013).

for match is materially lower than that for mismatch which
supports the predictive nature of the assay.
Cross-drug response and impact on clinical outcome. Assay
tumour responses differ by therapy, and cross-drug resistance
was evident in this population. Of 262 tumours, 123 (47%)
were identified as non-sensitive to all tested therapies (RA),
845
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0.6
Sensitive
0.4

0.6

Status

No. Median PFS (mo)

RA
RP
SP
SA

123
64
51
24

5.91
5.86
8.80
9.06

0.4

Non-sensitive
0.2

0.2
HR=0.67 (95% Cl: 0.50–0.91
Log-rank test: P=0.009

0.0

0.0
0

6

12

18
Time (months)

24

30

36

Figure 1. Association of clinical treatment assay result (match) with
PFS. Patients treated with assay-sensitive treatments experienced a
median PFS of 8.8 months, whereas those treated with assay-non-sensitive
treatments experienced a median PFS of 5.9 months. Reproduced by
kind permission of Elsevier from Rutherford et al (2013).

20.0
Mean HR=0.81 (95% range: 0.66–0.99)
17.5

Distribution (%)

15.0

HR=0.67
(from match)

12.5
10.0
7.5
5.0
2.5

3.4%

0.0
0.50 0.55 0.60 0.65 0.70 0.75 0.80 0.85 0.90 0.95 1.00 1.05 1.10 1.15 1.20
Hazard ratios (HRs) from mismatch (3000 repeats)
20.0
Mean HR=0.88 (95% range: 0.70–1.09)

17.5

Distribution (%)

15.0

HR=0.66
(from match)

12.5
10.0
7.5
5.0
2.5

0.7%

0.0

0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0 5 0
0.5 0.5 0.6 0.6 0.7 0.7 0.8 0.8 0.9 0.9 1.0 1.0 1.1 1.1 1.2 1.2 1.3 1.3 1.4
Hazard ratios (HRs) from mismatch (3000 repeats)

Figure 2. Association of randomly selected assay result (mismatch)
with PFS. The mean HR for mismatch was calculated from repeated
(3000) simulations in univariate (A) and multivariate (B) analyses.

whereas 24 (9%) were defined as sensitive to all tested therapies
(SA); the remainder (44%) were sensitive to at least one therapy.
For those patients showing a heterogeneous pattern of response, 51
were treated with sensitive therapies (SP), and 64 were treated with
non-sensitive therapies (RP). The median PFS was 9.1, 8.8, 5.9 and
5.9 months for SA, SP, RP and RA, respectively, with significant
846

0

6

12

18

24

30

36

Time (months)
RA

RP

SP

SA

Figure 3. PFS for patients displaying homogeneous vs heterogeneous
assay responses. Patients were classified into four groups based on
their calculated multiple drug response index (MDRI) and administered
clinical treatment: sensitive to all assayed therapies (MDRI ¼ 100%) and
treated with a sensitive therapy (SA), sensitive to some therapies
(0oMDRIo100%) and treated with a sensitive therapy (SP), nonsensitive to all therapies (MDRI ¼ 0) and treated with a non-sensitive
therapy (RA), and non-sensitive to some therapies (0oMDRIo100%)
and treated with a non-sensitive therapy (RP).

difference between SA þ SP vs RA þ RP, as previously shown
(HR ¼ 0.67, 95% CI ¼ 0.50–0.91, P ¼ 0.009; Rutherford et al, 2013),
as well as approximately 3 months difference between SA vs RA
and between SP vs RP, but without meaningful differences between
SP vs SA or between RP vs RA (Figure 3).
The impact of cross-drug response on PFS was further assessed
based on MDRI using the Cox model. In univariate analysis,
patients whose tumours were sensitive to more therapies (i.e.,
higher MDRI) experienced better prognoses, as expected
(HR ¼ 0.96, 95% CI ¼ 0.92–0.99, P ¼ 0.034). However, MDRI was
no longer significant in multivariate analysis (HR ¼ 1.02, 95%
CI ¼ 0.95–1.09, P ¼ 0.629), whereas the association between assay
result for administered therapy and PFS remained evident
(HR ¼ 0.60, 95% CI ¼ 0.36–1.02, P ¼ 0.057; Table 2).
Chemoresponse assay scores for the seven single-agent therapies
were further evaluated using two-dimensional clustering analysis.
Therapies are represented along the x axis, with carboplatin,
cisplatin and doxorubicin clustering together and paclitaxel,
docetaxel, topotecan and gemcitabine clustering together. Along
the y axis, patients were classified into three clusters (A, B and C),
consisting of 63%, 36% and 1% of the study population,
respectively (Figure 4). Cluster C was excluded from the analysis
owing to the limited number of patients in this group. There is no
evidence that this unsupervised clustering was significantly
associated with either clinical characteristics or patient outcome
(data not shown). These results, together with the data shown in
Figure 3 and Table 2, indicate this assay is likely not prognostic of
outcome independent of treatment, like some clinical factors (e.g.,
age, stage, grade, etc.). Rather, the assay’s prognostic value (as
observed in the mismatch analysis) is likely attributed to crossdrug response (i.e., correlation of assay results for randomly
selected therapies with assay result for clinically administered
therapy), as anticipated.
DISCUSSION

The development and validation of predictive markers has become
increasingly vital to improving patient outcomes, especially in the
www.bjcancer.com | DOI:10.1038/bjc.2014.375
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Colour key

Table 2. Univariate and multivariate analyses of the association of PFS
with chemoresponse assay results

Univariate analysis
HR (95% CI)

P-value

Multivariate analysis
HR (95% CI)

P-value

2 4 6 8 10
Assay score

Age
Increasing per
10 years

1.09 (0.97–1.23)

0.160

1.07 (0.93–1.24)

0.349

1.24 (0.94–1.65)

0.136

1.12 (0.80–1.57)

0.518

1.29 (0.97–1.72)

0.081

1.37 (0.97–1.95)

0.076

1.14 (0.80–1.64)

0.462

1.12 (0.77–1.62)

0.562

o0.001

0.64 (0.47–0.87)

0.005

Histology

MDRI
Increasing each
ten percent

0.96 (0.92–0.99)

0.034

1.02 (0.95–1.09)

0.629

0.009

0.60 (0.36–1.02)

0.057

Chemoresponse assay results
Sensitive vs
non-sensitive

0.67 (0.50–0.91)

Abbreviations: CI ¼ confidence interval; ECOG ¼ Eastern Cooperative Oncology Group;
HR ¼ hazard ratio; PFS ¼ progression-free survival; PS ¼ performance status; MDRI ¼
multiple drug response index.

face of an increasing number of available therapies. The current
study investigated the association of specific treatment outcomes in
262 prospectively accrued persistent and recurrent EOC patients
with assay results blinded to the investigator and patient. Using
several approaches, the predictive value of a chemoresponse assay
was evaluated and supported.
The analyses conducted herein address common clinical
concerns regarding the predictive properties of a chemoresponse
assay (Markman, 2011), including the ability of the assay to discern
specific therapies that are likely to be more effective among the
multiple clinically relevant treatment options. Specifically, the
ability of a chemoresponse assay to identify treatment-specific
sensitivity has been questioned given the clinical and biological
factors that may limit the ability of an assay to be predictive of
patient response. For example, since cross-drug response to
different therapies is a common phenomenon in chemoresponse
assays and it is thought that patients can exhibit multidrug
resistance, there is concern that these factors may limit the
predictive ability of an assay. Furthermore, it is hypothesised that
the improved outcome observed for patients treated with assaysensitive therapies may be driven by the inherent biology of the
tumour represented by the chemoresponse profile (i.e., homogeneous sensitivity vs homogeneous resistance to all therapies),
suggesting that the assay may simply reflect the inherent
biological-based tumour behaviour and, hence, patient prognosis.
The studies described herein attempt to address each of these
concerns.
First, the match/mismatch analysis assesses whether cross-drug
response and correlated assay results across different therapies
www.bjcancer.com | DOI:10.1038/bjc.2014.375

Docetaxel

Paclitaxel

0.59 (0.45–0.76)

Topotecan

Plat sensitive vs
plat resistant

Gemcitabine

Platinum sensitivity status

Doxorubicin

C

3 vs 1 or 2

B

Tumour grade

Cisplatin

Serous vs others

Carboplatin

1 or 2 vs 0

A

ECOG PS

Figure 4. Two-dimensional clustering analysis based on
chemoresponse assay data for single-agent treatments. Therapies are
represented along the x axis, and patients are represented along the y
axis. Red indicates lower assay score (i.e., sensitive), and yellow
indicates higher assay score (i.e., resistant).

limit the predictive ability of the assay. This simple approach,
evaluating the ability of the assay to predict patient outcome based
on the assay result for the clinically administered therapy (match)
as compared with a randomly selected treatment assay result for
the same patient (mismatch), showed that the association of
outcome and assay result for match was stronger than for
mismatch (HR: 0.67 vs 0.81, respectively), indicating that a patient
receiving an assay-sensitive therapy would be more likely to
experience a better outcome than a patient treated empirically.
Next, the heterogeneity of assay response for a given patient to
multiple therapies was evaluated, showing that nearly half (44%) of
the patients included in the study demonstrated heterogeneous
assay response to all therapies tested (i.e., were sensitive to at least
one therapy tested, but not all), whereas the remainder were
homogeneously sensitive (9%) or non-sensitive (47%). Comparison
of PFS for heterogeneous patients vs those displaying homogeneous responses demonstrated that improved outcome in assaysensitive patients is unlikely due to the inherent (presumably
homogeneous) chemosensitivity of a tumour. Further, multivariate
analysis demonstrated that an increased or decreased percentage of
assay-sensitive results across all therapies tested was not associated
with patient outcome when the matched assay result was included.
Therefore, although tumour sensitivity or resistance to multiple
therapies is evident in a portion of recurrent EOC patients,
improved outcome was associated with clinical administration of a
sensitive therapy, regardless of whether that tumour displayed
homogeneous or heterogeneous assay responses.
Finally, unsupervised clustering analysis, based on assay results
for multiple single-agent therapies, was neither associated with
common clinical factors nor with patient outcome, further
supporting that this assay is not just reflective of intrinsic tumour
biology or common clinical factors normally associated with
tumour prognosis (i.e., not only prognostic).
With rapid advancements in cancer research and the number of
new therapies being developed, clinical interest lies in identifying
847
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predictive markers for personalised therapy. Although many
molecular-based biomarkers have been clinically accepted
(Cobleigh et al, 1999; Slamon et al, 2001; Amado et al, 2008;
Karapetis et al, 2008; Mok et al, 2009; Van Cutsem et al, 2009;
Rosell et al, 2012) and are supported by regulatory bodies’
approvals and inclusion in standardized treatment paradigms for
other cancer types (Allegra et al, 2009; Burstein et al, 2010; Keedy
et al, 2011; National Comprehensive Cancer Network, 2013b, c, d),
unfortunately, to date, no predictive markers have been clinically
validated for use in EOC. Although numerous clinical factors (e.g.,
age, stage, grade, histology) are used extensively in making
treatment decisions especially in the recurrent EOC setting, these
factors are limited in their ability to discern specific therapies that
are likely to be more effective in second-line treatment and beyond.
Clinical validation of prognostic and predictive markers requires
study designs that differ from those employed in traditional drug
trials (Institute of Medicine, 2011). Clinical validation for
prognostic markers is more straightforward, as only the clinical
outcomes between marker-positive and marker-negative patients
are compared within a cohort of uniformly treated patients. If a
marker is significantly associated with outcome when the effects of
other possible confounding factors are controlled, then the marker
is considered to be prognostic. In contrast, the clinical studies
required to demonstrate the clinical validation of predictive
markers are more complex. Often, data from previously conducted
randomized drug trials are employed to conduct such validations if
archived tissue is available and appropriate for the marker. This
strategy may be advantageous in certain instances where outcomes
require prolonged follow-up to achieve a meaningful difference in
survival.
Clinical study designs for markers have been extensively discussed
and reviewed in the literature (Simon and Maitournam, 2004;
Sargent et al, 2005; Freidlin et al, 2010; Tajik et al, 2013). The
biomarker-stratified design, which uses the marker status to guide
analysis but not to assign treatment, is considered to be more efficient
regarding required study sample size, can be used when the number
of markers and treatment choices is limited, and can investigate a
marker’s predictive properties. However, this approach is not directly
compatible with chemoresponse assays where a larger number of
therapies (multiple markers) are evaluated simultaneously (e.g., the
response profile of each therapy is considered to be a separate
marker). The biomarker-strategy design, in which patients are
randomized to two arms (assay-directed vs empirical treatment), is a
reasonable approach for evaluating multiple markers and has been
recommended for evaluation of chemoresponse assays (Blue Cross
and Blue Shield Association, 1995, 2000, 2002; Schrag et al, 2004;
Burstein et al, 2011). However, this design is inefficient in its use of
patients (i.e., large sample size not logistically feasible) and may not
clearly distinguish between better treatments in the marker arm vs
the standard of care arm (Freidlin et al, 2010; Buyse et al, 2011;
Ziegler et al, 2012; Buyse and Michiels, 2013; Center for Medical
Technology Policy, 2013). Furthermore, this approach has been
shown to be subject to a treating physician ‘learning effect’ bias
where, across the study duration, empirically selected treatments
became more similar to those indicated in the assay-informed arm, as
described by Cree et al (2007).
Over the last two decades, numerous assessments have called for
more thorough evaluation of the validation and justification of
chemoresponse assays for clinical use (Blue Cross and Blue Shield
Association, 1995, 2000, 2002; Schrag et al, 2004; Burstein et al,
2011). The study design uniformly recommended in these
assessments is based on the biomarker-strategy design, specifically
an interventional (i.e., treatment assigned by marker), randomized,
two-arm (assay-directed vs empiric treatment assignment) marker
study design. Although the design proposed in these assessments
can theoretically address a few markers simultaneously and has
been historically referenced as the ‘gold standard’, it would require
848
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a larger number of patients, would be subject to the physician bias
‘learning effect’ and, yet, still not able to cleanly evaluate the
predictive marker elements. Also, importantly, alternate
approaches to evaluating both predictive and prognostic marker
elements can be executed on a more achievable sample size
(Wieand, 2005). As a result, the biomarker-strategy approach is not
the only design that can effectively validate a predictive marker and
may not be the preferred approach (Center for Medical
Technology Policy, 2013).
The match/mismatch analysis method employed in this study
represents a promising alternate approach to validating a
chemoresponse assay, in that it has an achievable sample size,
retains the ability to assess both prognostic and predictive marker
properties and is appropriate for use with multiple markers (Simon
and Maitournam, 2004; Maitournam and Simon, 2005; Simon,
2005; Mandrekar and Sargent, 2009, 2010; Simon, 2010; Center for
Medical Technology Policy, 2013). This is especially important in
recurrent EOC where numerous, clinically-equivalent therapies are
available for use and enrolment of a large sample size is not
logistically feasible. Furthermore, this approach has been previously recommended for assessment of chemoresponse assays and
is expected to be able to evaluate whether the assay is predictive of
response (Wieand, 2005). This method does lack the ability to
assess each therapy/marker individually due to prohibitive sample
size requirements, which increases with each individual therapy/
marker evaluated.
In both the current analyses and the prior analysis reported by
Rutherford et al, the association of assay result with clinical
outcome was evaluated using two strata (sensitive vs nonsensitive), with the thresholds for each treatment predefined in
an external reference sample, independent of clinical outcome.
Analysis of quantitative data, such as a receiver operating
characteristic (ROC) curve, may further illustrate assay performance; however, due to the individualised nature of establishing
assay treatment concentrations and response category thresholds
for each distinct treatment, assay results cannot be directly
compared across different treatments (i.e., the assay result range
varies across individual treatments).
Clinical validations for chemoresponse assays, which simultaneously assess multiple markers/therapies, must be carefully
considered. Through further analysis of a prospective study and
by using several analytical approaches, the current study further
evaluated the clinical value of a chemoresponse assay. The results
provide reasonable evidence that this assay is a predictive marker,
with the capacity to discern specific therapies that are likely to be
more effective, and women with recurrent EOC may benefit from
assay-informed therapy selection.
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